In the world of asthma medication, there's a war approaching and GlaxoSmithKline (GSK) has just dodged the first bullet. The US Food and Drug Administration (FDA) has rejected Mylan's (US: MYL) first attempt at an unbranded version of GSK's top-selling respiratory drug Advair, thus delaying the inevitable sales decline of the original product.
To continue reading, register today
to enjoy limited access to the following:
- Daily trading news
- Funds coverage
- Features on big investment themes
- Comprehensive companies coverage
- Economic analysis